Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.42
AMRI's Cash to Debt is ranked higher than
59% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. AMRI: 1.42 )
AMRI' s 10-Year Cash to Debt Range
Min: 0.27   Max: 1216.19
Current: 1.42

0.27
1216.19
Equity to Asset 0.55
AMRI's Equity to Asset is ranked higher than
64% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. AMRI: 0.55 )
AMRI' s 10-Year Equity to Asset Range
Min: 0.32   Max: 0.96
Current: 0.55

0.32
0.96
Interest Coverage 16.08
AMRI's Interest Coverage is ranked higher than
53% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AMRI: 16.08 )
AMRI' s 10-Year Interest Coverage Range
Min: 1.52   Max: 1157.93
Current: 16.08

1.52
1157.93
F-Score: 7
Z-Score: 3.16
M-Score: -2.72
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 8.18
AMRI's Operating margin (%) is ranked higher than
85% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. AMRI: 8.18 )
AMRI' s 10-Year Operating margin (%) Range
Min: -36.35   Max: 46.92
Current: 8.18

-36.35
46.92
Net-margin (%) 5.14
AMRI's Net-margin (%) is ranked higher than
84% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. AMRI: 5.14 )
AMRI' s 10-Year Net-margin (%) Range
Min: -31.74   Max: 77.21
Current: 5.14

-31.74
77.21
ROE (%) 5.16
AMRI's ROE (%) is ranked higher than
86% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. AMRI: 5.16 )
AMRI' s 10-Year ROE (%) Range
Min: -25.79   Max: 112.9
Current: 5.16

-25.79
112.9
ROA (%) 2.85
AMRI's ROA (%) is ranked higher than
86% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. AMRI: 2.85 )
AMRI' s 10-Year ROA (%) Range
Min: -19.34   Max: 36.33
Current: 2.85

-19.34
36.33
ROC (Joel Greenblatt) (%) 10.73
AMRI's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. AMRI: 10.73 )
AMRI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -35.53   Max: 80.59
Current: 10.73

-35.53
80.59
Revenue Growth (%) 7.30
AMRI's Revenue Growth (%) is ranked higher than
81% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. AMRI: 7.30 )
AMRI' s 10-Year Revenue Growth (%) Range
Min: -1.5   Max: 78.2
Current: 7.3

-1.5
78.2
» AMRI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

AMRI Guru Trades in Q1 2013

Steven Cohen 42,143 sh (+145.9%)
Jim Simons 639,542 sh (+95.01%)
Murray Stahl 56,000 sh (unchged)
John Rogers Sold Out
Chuck Royce 1,446,284 sh (-8.65%)
» More
Q2 2013

AMRI Guru Trades in Q2 2013

Murray Stahl 56,000 sh (unchged)
Jim Simons 593,642 sh (-7.18%)
Chuck Royce 1,103,710 sh (-23.69%)
Steven Cohen 14,790 sh (-64.91%)
» More
Q3 2013

AMRI Guru Trades in Q3 2013

Joel Greenblatt 228,216 sh (New)
Jim Simons 596,942 sh (+0.56%)
Murray Stahl 56,000 sh (unchged)
Steven Cohen Sold Out
Chuck Royce 994,710 sh (-9.88%)
» More
Q4 2013

AMRI Guru Trades in Q4 2013

Chuck Royce 1,412,568 sh (+42.01%)
Joel Greenblatt 229,437 sh (+0.54%)
Murray Stahl 56,000 sh (unchged)
Jim Simons 512,600 sh (-14.13%)
» More
» Details

Insider Trades

Latest Guru Trades with AMRI

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-09-30 New Buy0.1%$10.81 - $13.72 $ 16.0931%228216
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 39.70
AMRI's P/E(ttm) is ranked higher than
51% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 28.80 vs. AMRI: 39.70 )
AMRI' s 10-Year P/E(ttm) Range
Min: 12.98   Max: 1328
Current: 39.7

12.98
1328
P/B 2.07
AMRI's P/B is ranked higher than
85% of the 787 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. AMRI: 2.07 )
AMRI' s 10-Year P/B Range
Min: 0.28   Max: 2.42
Current: 2.07

0.28
2.42
P/S 2.04
AMRI's P/S is ranked higher than
89% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. AMRI: 2.04 )
AMRI' s 10-Year P/S Range
Min: 0.31   Max: 3.06
Current: 2.04

0.31
3.06
PFCF 29.80
AMRI's PFCF is ranked higher than
62% of the 207 Companies
in the Global Biotechnology industry.

( Industry Median: 31.10 vs. AMRI: 29.80 )
AMRI' s 10-Year PFCF Range
Min: 11.16   Max: 1757
Current: 29.8

11.16
1757
EV-to-EBIT 23.22
AMRI's EV-to-EBIT is ranked lower than
52% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. AMRI: 23.22 )
AMRI' s 10-Year EV-to-EBIT Range
Min: 6.6   Max: 333.6
Current: 23.22

6.6
333.6

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 13.63
AMRI's Price/Net Current Asset Value is ranked lower than
57% of the 520 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. AMRI: 13.63 )
AMRI' s 10-Year Price/Net Current Asset Value Range
Min: 3.28   Max: 17.56
Current: 13.63

3.28
17.56
Price/Tangible Book 2.09
AMRI's Price/Tangible Book is ranked higher than
86% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. AMRI: 2.09 )
AMRI' s 10-Year Price/Tangible Book Range
Min: 0.44   Max: 8.94
Current: 2.09

0.44
8.94
Price/DCF (Projected) 2.19
AMRI's Price/DCF (Projected) is ranked higher than
74% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. AMRI: 2.19 )
AMRI' s 10-Year Price/DCF (Projected) Range
Min: 0.49   Max: 1.37
Current: 2.19

0.49
1.37
Price/Median PS Value 1.21
AMRI's Price/Median PS Value is ranked higher than
59% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. AMRI: 1.21 )
AMRI' s 10-Year Price/Median PS Value Range
Min: 0.25   Max: 15.07
Current: 1.21

0.25
15.07
Price/Graham Number 1.93
AMRI's Price/Graham Number is ranked higher than
74% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. AMRI: 1.93 )
AMRI' s 10-Year Price/Graham Number Range
Min: 0.84   Max: 5.83
Current: 1.93

0.84
5.83
Earnings Yield (Greenblatt) 4.30
AMRI's Earnings Yield (Greenblatt) is ranked higher than
59% of the 379 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. AMRI: 4.30 )
AMRI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 15.1
Current: 4.3

0.3
15.1
Forward Rate of Return (Yacktman) 0.46
AMRI's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. AMRI: 0.46 )
AMRI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -17.8   Max: 23.2
Current: 0.46

-17.8
23.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AYM.Germany
Albany Molecular Research, Inc., is a Delaware corporation incorporated on June 20, 1991. It is a contract research and manufacturing organization providing customers drug discovery, development and manufacturing services. The Company provides services and technologies that support the discovery and development of pharmaceutical products and the manufacturing of Active Pharmaceutical Ingredients (API) and drug product for existing and experimental new drugs. With locations in the United States, Europe, and Asia, it maintains geographic proximity and flexible cost models. It has also historically leveraged its drug-discovery expertise to execute on several internal drug discovery programs, which have progressed to the development candidate stage and in some cases into Phase I clinical development. It has partnered certain programs and is actively seeking to out-license its remaining programs to strategic partners for further development. The Company performs services including drug discovery, pharmaceutical development, and manufacturing of active ingredients and pharmaceutical intermediates for healthcare companies. The Company offers custom assay design and development services to clients in the pharmaceutical, biopharmaceutical and agrochemical industries who are starting from a unique target or who are supporting ongoing discovery programs. The Company offers screening capabilities, coupled with access to its sample collections, gives customers the tools to efficiently identify and optimize compounds. The Company's CADD services use sophisticated computational software and techniques to help identify novel hits or leads against selected therapeutic targets, as well as to support medicinal chemistry optimization programs. The Company has organized its activities into two distinct segments: Large Scale Manufacturing (LSM) and Discovery, Drug Development and Small Scale Manufacturing (DDS). The Company's LSM activities include pilot to commercial scale production of active pharmaceutical ingredients and intermediates, sterile syringe and vial filling, and high potency and controlled substance manufacturing and its remaining activities, including drug discovery, optimization, drug development, and small scale commercial manufacturing represent its DDS business segment. The manufacture, transportation and storage of its products are subject to certain international, Federal, state and local laws and regulations. The Company faces competition based on a number of factors, including size, relative expertise and sophistication, quality and costs of identifying and optimizing potential compounds and speed and costs of optimizing chemical processes. The manufacture, transportation and storage of its products are subject to certain international, Federal, state and local laws and regulations.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide